INSPIREMD, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.96 USD | +2.35% |
|
-6.22% | -30.25% |
| Mar. 06 | Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024 | |
| Mar. 06 | Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M | MT |
Financials (USD)
| Sales 2024 * | 7.09M | Sales 2025 * | 14.65M | Capitalization | 44.86M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 6.32 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.06 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 66 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on InspireMD, Inc.
More press releases
| 1 day | +2.35% | ||
| 1 week | -6.22% | ||
| Current month | -17.30% | ||
| 1 month | -12.89% | ||
| 3 months | -33.33% | ||
| 6 months | -39.51% | ||
| Current year | -30.25% |
1 week
1.81
2.14
1 month
1.812.45
Current year
1.813.24
1 year
1.033.85
3 years
0.817.32
5 years
0.81112.65
10 years
0.811 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Marvin Slosman
CEO | Chief Executive Officer | 60 | 19-12-31 |
Craig Shore
DFI | Director of Finance/CFO | 62 | 11-03-30 |
Juan Rigla
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Roubin
BRD | Director/Board Member | 76 | 20-10-12 |
Marvin Slosman
CEO | Chief Executive Officer | 60 | 19-12-31 |
Thomas Kester
BRD | Director/Board Member | 77 | 16-09-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.96 | +2.35% | 8 478 |
| 24-04-25 | 1.915 | +3.51% | 13,077 |
| 24-04-24 | 1.85 | -6.33% | 7,395 |
| 24-04-23 | 1.975 | +3.40% | 14,315 |
| 24-04-22 | 1.91 | -8.61% | 21,370 |
Delayed Quote Nasdaq, April 26, 2024 at 11:57 am EDT
More quotes
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.915
USD
Average target price
4.5
USD
Spread / Average Target
+134.99%
| 1st Jan change | Capi. | |
|---|---|---|
| -30.25% | 44.86M | |
| -2.37% | 185B | |
| -3.65% | 105B | |
| -5.01% | 66.59B | |
| +2.26% | 54.66B | |
| +16.70% | 47.78B | |
| +4.06% | 41.26B | |
| +2.42% | 26.95B | |
| +2.48% | 26.37B | |
| +12.96% | 24.8B |
- Stock Market
- Equities
- NSPR Stock
